RxDoctor Payments Data

Muhammad Nawaz, APRN

Psychiatric/Mental Health · West Palm Beach, FLNPI 1750850863

Payments from drug & device makers

$3,511in general payments, 2019–2025

Across 77 payments — averaging $45.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$655
  • Alkermes, Inc.$542
  • AbbVie$463
  • Teva Pharmaceuticals USA, Inc.$416
  • Neurocrine Biosciences, Inc.$324
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$277
  • plus $834 from 9 others

What the payments were for

  • Food & beverage$3,43398%
  • Education$782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,511 in reported general payments places this provider in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$65,528
Medicare patients
154
Services billed
930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate143$482,757
Abilify MaintenaAripiprazole69$196,386
IngrezzaValbenazine Tosylate15$112,151
RexultiBrexpiprazole31$46,177
Risperdal ConstaRisperidone Microspheres30$34,705
Aripiprazole220$29,619
VraylarCariprazine Hcl13$17,738
Paliperidone ErPaliperidone67$9,296
Quetiapine Fumarate644$8,649
Clozapine63$7,806
TrintellixVortioxetine Hydrobromide13$6,485
Divalproex Sodium234$6,336
Duloxetine Hcl235$5,879
Fluphenazine Hcl49$5,720
Lurasidone Hcl31$5,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$655$517,462173 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$214$242,563100 claims
Neurocrine Biosciences, Inc.Ingrezza$324$112,15115 claims
AbbVieVraylar$463$17,73813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →